Interestingly, in the context of regulatory approval trial, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RA) showed a reduced incidence of a major adverse cardiovascular event (MACE), namely cardiovascular death and heart failure (HF) hospitalizations [2,3]. The gene discussed is GCG; the disease is hydrops fetalis.